Founded in 2000 on technology developed at the Ontario Cancer Institute and University of Toronto, Molecular Templates had difficulty securing add-on funding in its home country following a $1.5 million investment earlier this decade.
Burrill promotes Aynechi, Vygantas, and Patel; UVA Patent Foundation honors Mugler and Brookeman as inventors of the year; and Balser to succeed Jacobson as vice chancellor for health affairs at Vanderbilt
The issue is divisive in that results from a comparative effectiveness study could alter how insurers reimburse certain drugs and diagnostics, which could in turn change physicians' prescribing habits.
After going through a restructuring phase at the end of last year in which it temporarily laid off its entire staff, LightSpeed continues to develop its optical detection technology and plans to test it with a new sequencing chemistry this year.
"We don't want to be part of a commodity market with a lot of close competition," said Peer Stähler, Febit's chief scientific officer. "There are at least 20 companies worldwide that are competing to sell the cheapest genes."
Dana-Farber Cancer Institute's Center for Cancer Computational Biology, GenoLogics, Johns Hopkins National Heart, Lung and Blood Institute Proteomics Center, AstraZeneca, BioWisdom, Physiomics, Eli Lilly, Applied Biosystems, Golden Helix
The company aims to tackle the two major issues in the antibody field — poor quality and too few antibodies — by defining a so-called "affome," an antibody set against all proteins in the human proteome.
CGC Genetics, Nuvera Biosciences, Veridex, ImaGenes, CapitalBio, Fisher Healthcare, Osmetech, National Institutes of Health, Clinical Data, Cogenics, UK Biotechnology and Biological Sciences Research Council
The New Zealand firm, which is "evaluating all options," has also been unable to secure the more than $1 million it is owed for selling its stake in a biofuels shop, or to find funding from a government technology-investment group.